Year 2021 (55)

Edition nr. 10

PCSK9 inhibitors for familial hypercholesterolaemia

Melvin Lafeber, Gerard A. Rongen
Nr 10|2021 (55)|Page 108-115|Main article|doi: 10.35351/gebu.2021.10.20|26-11-2021

An elevated LDL-cholesterol concentration is one of the risk factors for atherosclerotic vascular disease that can be modified by lifestyle interventions or medication. Due to their greatly elevated LDL-cholesterol level, patients with familial h ...

In short Read article

Primary prevention using a polypill

Frans M. Helmerhorst, Anton J.F.A. Kerst, Niels H. Schut, Marielle A.E. Nieuwhof
Nr 10|2021 (55)|Page 101-107|New|doi: 10.35351/gebu.2021.10.19|26-11-2021

Summary The polypill, a combination therapy to prevent cardiovascular diseases like myocardial infarction, does not yet appear to be a wonder drug. Research into primary prevention using a polypill for patients at low risk of cardiovascular dise ...

In short Read article